You are here

Regeneron

US to pay up to $2.6B for more doses of Regeneron's COVID-19 antibody drug

US to pay up to $2.6B for more doses of Regeneron's COVID-19 antibody drug

BioPharma Dive

government contracts

Flag link:

JPM: Regeneron has spoken with the FDA about odronextamab hold, hopes to get patients back soon

JPM: Regeneron has spoken with the FDA about odronextamab hold, hopes to get patients back soon

Fierce Biotech

B-cell non-Hodgkin lymphoma

Flag link:

Clinical developments over the holidays

Clinical developments over the holidays

EP Vantage

Aprea Therapeutics

Arcturus Therapeutics

Axsome Therapeutics

clinical trials

Flag link:

Regeneron says it will continue trial of COVID antibody cocktail as latest data show positive results

Regeneron says it will continue trial of COVID antibody cocktail as latest data show positive results

Marketwatch

Flag link:

Roche eyes an uncertain market for faricimab

Roche eyes an uncertain market for faricimab

EP Vantage

diabetic macular edema

Flag link:

Roche's bispecific matches Regeneron's Eylea in phase 3 trials

Roche's bispecific matches Regeneron's Eylea in phase 3 trials

Fierce Biotech

diabetic macular edema

clinical trials

bispecific antibodies

Flag link:

Lilly and Regeneron COVID-19 antibodies are available all over the U.S. Why aren't they getting to more patients?

Lilly and Regeneron COVID-19 antibodies are available all over the U.S. Why aren't they getting to more patients?

Fierce Pharma

Flag link:

13 drugmakers contracted by Operation Warp Speed in 2020

13 drugmakers contracted by Operation Warp Speed in 2020

Beckers Hospital Review

Operation Warp Speed

Emergent BioSolutions

Moderna Therapeutics

Flag link:

Novartis raises the temp on Eylea rivalry with head-to-head trial win for Beovu in diabetic macular edema

Novartis raises the temp on Eylea rivalry with head-to-head trial win for Beovu in diabetic macular edema

Endpoints

diabetic macular edema

Flag link:

Regeneron's blood cancer hopeful odronextamab hit with FDA partial hold across several trials

Regeneron's blood cancer hopeful odronextamab hit with FDA partial hold across several trials

Fierce Biotech

clinical trials

B-cell non-Hodgkin lymphoma

Flag link:

#ASH20: In a multiple myeloma showdown, Regeneron marches out new PhI data for its BCMA bispecific

#ASH20: In a multiple myeloma showdown, Regeneron marches out new PhI data for its BCMA bispecific

Endpoints

Multiple Myeloma

clinical trials

Flag link:

Regeneron, UPenn to use gene therapy tools to deliver a COVID-19 antibody drug

Regeneron, UPenn to use gene therapy tools to deliver a COVID-19 antibody drug

BioPharma Dive

Flag link:

Regeneron COVID-19 drug, used to treat Trump, cleared for emergency use

Regeneron COVID-19 drug, used to treat Trump, cleared for emergency use

BioPharma Dive

Emergency Use Authorization

Flag link:

Eli Lilly's Covid-19 partner AbCellera pays $90M for some very special mice as IPO rumors heat up

Eli Lilly's Covid-19 partner AbCellera pays $90M for some very special mice as IPO rumors heat up

Endpoints

monoclonal antibodies

Flag link:

After Pfizer's vaccine data, analysts say COVID19 drugmakers face questions about long-term sales prospects

After Pfizer's vaccine data, analysts say COVID19 drugmakers face questions about long-term sales prospects

Fierce Pharma

Gilead Sciences

clinical trials

Flag link:

Regeneron hopes U.S. will authorize coronavirus antibody drug soon

Regeneron hopes U.S. will authorize coronavirus antibody drug soon

Yahoo/Reuters

Flag link:

Regeneron Posts Better-Than-Expected Third-Quarter Earnings

Regeneron Posts Better-Than-Expected Third-Quarter Earnings

TheStreet.com

Flag link:

Regeneron hit by 'safety signal' for COVID-19 cocktail as data board tells pharma to stop enrolling sicker patients

Regeneron hit by 'safety signal' for COVID-19 cocktail as data board tells pharma to stop enrolling sicker patients

Fierce Biotech

clinical trials

Flag link:

Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted first-line use in lung cancer

Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted first-line use in lung cancer

Fierce Pharma

priority review

non-small cell lung cancer

Flag link:

Regeneron posts second look on Covid-19 antibody cocktail, boosting its case for EUA — but what about symptom alleviation?

Regeneron posts second look on Covid-19 antibody cocktail, boosting its case for EUA — but what about symptom alleviation?

Endpoints

Emergency Use Authorization

Flag link:

Pages